Effectiveness and Economic Impact Associated With a Program for Outpatient Management of Acute Deep Vein Thrombosis in a Group Model Health Maintenance Organization
Donald J. Tillman, PharmD;
Scott L. Charland, PharmD;
Daniel M. Witt, PharmD
Arch Intern Med. 2000;160:2926-2932.
Background Controlled clinical trials have demonstrated that outpatient administration of low-molecular-weight heparin to patients with acute deep vein thrombosis (DVT) provides safety and efficacy equivalent to that of traditional inpatient therapy with unfractionated heparin. Whether favorable results reported in controlled clinical trials are achievable in clinical practice is an important consideration.
Methods Appropriate patients with objectively diagnosed DVT were treated as outpatients with low-molecular-weight heparin and warfarin sodium according to an approved guideline. The primary end point for analysis consisted of objectively diagnosed symptomatic recurrent thromboembolism or major bleeding within a 90-day evaluation period. The incremental cost incurred by the organization while using the outpatient DVT treatment guideline was determined. Incremental cost savings of the outpatient DVT treatment program were determined based on the cost that would have accrued had the patient been admitted to the hospital for treatment with unfractionated heparin.
Results We enrolled 391 patients (91.4%) in the outpatient DVT treatment program. Of these, 373 (95.4%) completed 90 days of therapy without reaching the primary end point. The percentage of patients reaching the primary outcome measure (4.6%) fell within the range of patients enrolled in controlled clinical trials (3.5%-9.4%). During the 2-year program evaluation, total cost savings of $1,108,587 were realized.
Conclusions Outpatient treatment of acute DVT can be managed safely and effectively in clinical practice. The potential savings associated with outpatient DVT treatment are substantial.
From the Clinical Pharmacy Anticoagulation Service (Drs Tillman and Witt) and Clinical Pharmacy Services (Dr Charland), Kaiser Permanente Colorado Region; Department of Pharmacy, Exempla St Joseph's Hospital (Dr Charland); and Department of Pharmacy Practice (Adjoint), University of Colorado School of Pharmacy (Drs Tillman, Charland, and Witt), Denver. Dr Charland is now with Roche Laboratories, Denver.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(19):3010-3011.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum
Garcia et al.
The Annals of Pharmacotherapy 2008;42:979-988.
ABSTRACT
| FULL TEXT
Initial management of deep venous thrombosis in the outpatient setting
Groce
Am J Health Syst Pharm 2008;65:866-874.
FULL TEXT
Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin
Spyropoulos
CLIN APPL THROMB HEMOST 2008;14:63-74.
ABSTRACT
Early discharge of patients with pulmonary embolism: a two-phase observational study
Davies et al.
Eur Respir J 2007;30:708-714.
ABSTRACT
| FULL TEXT
Management of Venous Thromboembolism: A Systematic Review for a Practice Guideline
Segal et al.
ANN INTERN MED 2007;146:211-222.
ABSTRACT
| FULL TEXT
Effect of a Centralized Clinical Pharmacy Anticoagulation Service on the Outcomes of Anticoagulation Therapy
Witt et al.
Chest 2005;127:1515-1522.
ABSTRACT
| FULL TEXT
Costs and Clinical Outcomes Associated With Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Bridging in Patients Receiving Long-term Oral Anticoagulant Therapy
Spyropoulos et al.
Chest 2004;125:1642-1650.
ABSTRACT
| FULL TEXT
Management of Acute Proximal Deep Vein Thrombosis* : Pharmacoeconomic Evaluation of Outpatient Treatment With Enoxaparin vs Inpatient Treatment With Unfractionated Heparin
Spyropoulos et al.
Chest 2002;122:108-114.
ABSTRACT
| FULL TEXT
Eligibility criteria for home treatment of DVT vary
Vinson
BMJ 2001;323:866-866.
FULL TEXT
|
